...
机译:Front-Line Daratumumab-VTD与ASCT符合条件多骨髓瘤的符合条件的标准 - 匹配调整后的间接比较
Hop Hotel Dieu Univ Hosp Serv Hematol Clin F-44000 Nantes France;
Inst Univ Canc Oncopole F-31100 Toulouse France;
Univ Lille CHU Lille Serv Malad Sang F-59000 Lille France;
CHU Poitiers Hop Miletrie F-86021 Poitiers France;
Univ Hosp Bordeaux Hosp Haut Leveque Dept Hematol F-33600 Bordeaux France;
Ingress Hlth NL-3012 NJ Rotterdam Netherlands;
Ingress Hlth NL-3012 NJ Rotterdam Netherlands;
CHU Dijon Hop Bocage F-21000 Dijon France;
Ctr Hosp Reg Univ Tours Hop Bretonneau F-37000 Tours France;
Vrije Univ Amsterdam Amsterdam UMC Canc Ctr Amsterdam Dept Hematol NL-1182 DB Amsterdam;
Univ Hosp Heidelberg Internal Med 5 D-69120 Heidelberg Germany;
Univ Med Ctr Hamburg Eppendorf D-20251 Hamburg Germany;
AK Altona Asklepios Tumorzentrum Hamburg D-20099 Hamburg Germany;
Univ Hosp Heidelberg Dept Internal Med 5 D-69120 Heidelberg Germany;
Univ Hosp Heidelberg Internal Med 5 D-69120 Heidelberg Germany;
Univ Hosp Heidelberg Internal Med 5 D-69120 Heidelberg Germany;
Janssen Res &
Dev B-2340 Beerse Belgium;
Janssen Res &
Dev LLC NL-2333 Leiden Netherlands;
Janssen Res &
Dev LLC NL-2333 Leiden Netherlands;
Evidera PPD Montreal PQ B0E 2K0 Canada;
Evidera PPD Montreal PQ B0E 2K0 Canada;
Janssen Global Serv Raritan NJ 08869 USA;
Janssen Global Serv Raritan NJ 08869 USA;
Janssen Global Serv Raritan NJ 08869 USA;
Janssen Global Serv Raritan NJ 08869 USA;
Erasmus MC Canc Inst NL-3015 GD Rotterdam Netherlands;
daratumumab; multiple myeloma; newly diagnosed; standard of care; transplant eligible;
机译:Panobinostat Plus Bortezomib与近年三体醛患者在复发和/或难治性多发性骨髓瘤中:使用患者级数据的匹配调整的间接治疗比较生存结果的比较
机译:硼替佐米,Melphalan和泼尼松(VMP)改性剂量方案对先前未经处理的,移植的多种骨髓瘤患者(MM)的影响:匹配调整的间接比较
机译:评价使用匹配调整的间接比较的多发性硬化症中自体造血干细胞移植与疾病修饰治疗的临床效果:欧洲骨骼和骨髓移植社会的自身免疫疾病工作党(ADWP)的探索性研究(EBMT)
机译:间接烃杂交体与间接 - 烃,负荷燃料电池车辆的能量使用比较
机译:从整体角度看待人格会提高其预测效用吗?比较多元回归,模糊聚类分析和间接混合建模以预测领导力有效性。
机译:单克隆抗体与组蛋白脱乙酰基酶抑制剂联合硼替佐米或来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤:随机对照试验的间接比较荟萃分析
机译:欧沙米多多氟化葡聚糖复发多发性硬化的匹配调整的间接治疗比较
机译:间接液化应用中浆料与固定床反应器成本的比较。最终报告的补充:用于间接液化应用的浆料反应器的设计。